ABBOTT LABORATORIES — Director's Dealing 2017

Feb 23, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-02-17

Reporting Person: Funck Robert E (Vice President, Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-17	Common shares without par value	A	7060	—	Acquired	92079	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-17	Option (right to buy)	$44.40	A	48831	Acquired	2027-02-16	Common shares (48831)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	16654	Indirect
Common shares without par value	500	Indirect
Common shares without par value	500	Indirect

Footnotes

F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2017.

F3: The reporting person disclaims beneficial ownership of all securities held by his daughter.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,277 on 2/17/2018, 16,277 on 2/17/2019, and 16,277 on 2/17/2020.